Accelerated Biosciences and Pluristyx Announce Availability of Human Trophoblast Stem Cell (hTSC) Derived iPSCs
Accelerated Biosciences, a regenerative medicine innovator of proprietary human trophoblast stem cells (hTSCs), announced an agreement for Pluristyx, Inc., an advanced therapy tools and services biotechnology company, to provide iPSCs derived from hTSCs procured under Good Tissue Practices (GTP) for research evaluation.
Finding the ideal source of stem cells remains a challenge in cell and gene therapy. hTSCs overcome these challenges as they are ethically sourced, scalable, immune-privileged, pathogen-free, and chromosomally stable even at high population doublings. As Accelerated Biosciences’ CDMO partner, Pluristyx reprogrammed hTSCs to iPSCs with a footprint-free, proprietary mRNA method that yields highly pure stem cells with demonstrated capacity to form all three tissue types, including terminal differentiation into NK cells with superior cytolytic activity. hTSC-iPSCs are available in Pluristyx’s unique Ready-to-Differentiate® format (RTD®), allowing for rapid evaluation by eliminating the need for expansion out of thaw. Because hTSC-iPSCs are sourced under GTP, commercial partners can transition to a clinical-grade version when appropriate.
“We are thrilled to present our hTSC-iPSC platform as a new starting cell source for therapeutic companies. Our platform provides all of the business advantages and reduced risks. Clinical grade hTSC-iPSCs will be available in 2023 with a complete regulatory support package,” said Yuta Lee, Chief Executive Officer of Accelerated Biosciences.
“Pluristyx is excited to offer iPSCs derived from Accelerated Biosciences’ unique hTSC starting material. These iPSCs robustly form differentiated cells from all three lineages and are derived under GTP and they are not associated with any living human or embryo, making them an exceptional starting material for next generation cell-based therapies. Available in our RTD® format, interested groups can accelerate their internal evaluation and rapidly transition to a clinical-grade version suitable for therapeutic manufacturing,” said Benjamin Fryer, Chief Executive Officer of Pluristyx.
About Accelerated Biosciences
Accelerated Biosciences is a private regenerative medicine company commercializing the hTSC platform, discovered by physician and researcher, Professor Jau-Nan Lee, MB, MD, PhD. Accelerated Biosciences holds a proprietary source of hTSCs with a robust intellectual property estate. Accelerated Biosciences’ mission is to leverage its renewable, immune-privileged human cell source to accelerate cures to patients and to make gene and cell therapy affordable to all in need. For more information about Accelerated Biosciences, visit www.acceleratedbio.com or email mmolsbergen@c14consultinggroup.com.
About Pluristyx
Pluristyx is a privately held biotechnology company offering consulting, wet-lab and GMP banking services, and pluripotent stem cell products to support novel therapeutic developers. Pluristyx helps industry and academic researchers solve manufacturing and analytical challenges in cryopreservation, drug development, regenerative medicine, and cell and gene therapy. The Pluristyx team has decades of experience supporting every stage of cell therapy product development, from cell banking to drug product manufacturing including analytical testing and release of clinical grade cell therapy products. For more information about Pluristyx, visit www.pluristyx.com or email Kaye Reiter, PhD, JD at kreiter@pluristyx.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220504005149/en/
Contact information
Yuta Lee
Accelerated Biosciences
yuta.lee@acceleratedbio.com
(424) 281-9882
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom